Distribution of Newly Issued Shares and Share Warrants by Issuer

million comparing to the net profit of Baht 1 million and Baht 50 million, respectively, in the same period last year. During this pandemic period, the Company has carefully managed the situation in all

were back on track with 44.5% growth YoY and 3.4% growth QoQ. - In Q1’19, the Company maintained its leadership position with total market share of 31.1% in Brain and Body Boost (“BBB”) products which

from our subsidiary, the Special Purpose Vehicle project (SPV) and well-managed funding cost. However, finance cost in the third quarter of 2018 accounted for 10%. The average funding cost decreased from

company still managed to maintain the gross profit margin at 39.9% and started to realize the profit from 2 new completed joint venture condominium projects (Joint Venture) with Nomura Real Estate

hotel business, gain from sales of long-term investment, an increase in the share of profit from investment, and a decrease in depreciation and amortization. In 3Q18, Dusit Thani PLC (“the Company

be a potential market in the future. For Medical Devices; There is still intense competition in both domestic and foreign markets. Market leaders use price strategies to gain market share. But the

Expenses (1,775.1) (36.6%) (1,720.2) (36.5%) +54.9 +3.2% Add: Share of Profit/(Loss) from Investments (by equity method) 9.1 0.2% 12.0 0.3% -2.9 -24.2% EBITDA 999.4 20.6% 914.1 19.4% +85.3 +9.3% Less

in Hotel Business. Other Business growth came from the gain from the sale of investments, the share of profit from investment in food business (as invested in 1Q18), and gain on foreign exchange rate

efficiently managed around 8.3% of total revenue. The provision of bad debts as a % of postpaid and broadband revenue was 2.3% lower than 2Q23 at 2.4%. Profitability 3Q23 EBITDA was at Bt23,674mn, increasing